Financial Performance - The company's revenue for Q1 2023 was ¥588,724,855.57, a decrease of 4.07% compared to ¥613,719,586.39 in the same period last year[3] - Net profit attributable to shareholders was ¥4,536,891.13, representing a significant increase of 108.34% from a loss of ¥54,380,193.73 in the previous year[3] - The net cash flow from operating activities improved to ¥54,977,540.05, a remarkable increase of 467.27% compared to a negative cash flow of ¥14,969,306.51 in the same period last year[3] - Basic earnings per share rose to ¥0.01, up 112.50% from a loss of ¥0.08 per share in the previous year[3] - Total operating revenue for Q1 2023 was CNY 588,724,855.57, a decrease of 4.8% compared to CNY 613,719,586.39 in the same period last year[18] - The company reported a net loss of CNY 495,579,610.22, slightly improved from a loss of CNY 500,116,501.35 in the previous year[16] - The net profit for Q1 2023 was ¥8,281,817.19, a significant recovery from a net loss of ¥41,900,248.37 in the same period last year, marking a turnaround of over 119%[19] - Operating profit reached ¥15,158,572.24, compared to an operating loss of ¥41,298,471.93 in Q1 2022, indicating a strong operational improvement[19] - The company reported a total comprehensive income of ¥3,899,115.34, recovering from a comprehensive loss of ¥42,054,654.04 in the same quarter last year[20] - Basic and diluted earnings per share were both ¥0.01, compared to a loss per share of ¥0.08 in Q1 2022, indicating a positive shift in profitability[20] Assets and Liabilities - Total assets at the end of the reporting period were ¥9,320,480,655.95, a slight decrease of 0.35% from ¥9,353,000,538.98 at the end of the previous year[3] - Total liabilities decreased to CNY 6,498,399,773.40 from CNY 6,534,818,771.77, a decline of 0.56%[16] - The total equity increased marginally to CNY 2,822,080,882.55 from CNY 2,818,181,767.21, reflecting stability in shareholder value[16] Cash Flow and Investments - Cash and cash equivalents decreased to CNY 142,992,750.49 from CNY 166,503,309.05, a decline of 14.1%[15] - The cash flow from operating activities generated a net inflow of ¥54,977,540.05, a significant improvement from a net outflow of ¥14,969,306.51 in Q1 2022[21] - Investment activities resulted in a net cash outflow of ¥20,344,101.11, contrasting with a net inflow of ¥282,865,481.43 in Q1 2022, highlighting a shift in investment strategy[23] Shareholder Information - The total number of common shareholders at the end of the reporting period is 56,764[8] - The largest shareholder, Guangzhou Kunlun Investment Co., Ltd., holds 23.09% of shares, with 152,709,621 shares pledged and 16,987,024 shares frozen[8] - The top ten shareholders collectively hold significant stakes, with the second-largest shareholder holding 4.06%[8] - The company has a total of 3,890,503 restricted shares at the end of the reporting period, with no shares released during the current period[9] Legal Matters - The company is involved in multiple legal disputes, including a contract dispute with a total execution amount of 58,912,000 RMB and another for 122,555,968 RMB[11] - The company has reached a settlement in a previous dispute but is facing enforcement actions due to unpaid amounts[11] - The company is committed to normal production operations while monitoring the progress of legal matters[12] Operating Costs and Expenses - The company reported a 41.33% increase in taxes and surcharges, attributed to higher tax obligations during the reporting period[6] - The company experienced a 305.87% increase in operating expenses, primarily due to an increase in estimated liabilities[6] - Total operating costs decreased to CNY 587,997,301.38 from CNY 713,529,042.61, representing a reduction of 17.6%[18] - Research and development expenses increased to CNY 17,941,867.46, up from CNY 14,074,755.90, reflecting a focus on innovation[18] - The company incurred a total of ¥6,828,584.34 in non-operating expenses, which is a significant increase from ¥1,682,436.25 in the previous year, indicating higher costs in this area[19] Inventory and Cash Management - Inventory increased to CNY 507,634,706.79 from CNY 467,074,930.98, an increase of 8.6%[15] - The cash and cash equivalents at the end of the period stood at ¥85,772,717.82, down from ¥328,374,768.80 at the end of Q1 2022, reflecting a decrease of approximately 73.9%[23] - Financing activities led to a net cash outflow of ¥75,181,381.45, compared to a net outflow of ¥111,112,301.34 in the same quarter last year, indicating improved cash management in financing[23] Profitability and Cost Management - Gross profit margin improved to 0.12% from a negative margin in the previous year, indicating better cost management[18] - Non-recurring gains and losses totaled ¥1,436,883.89, primarily due to government subsidies and asset disposal gains[4]

Financial Performance - The company achieved operating revenue of CNY 2,187,069,901.40, a decrease of 26.38% year-on-year[23]. - The net profit attributable to shareholders was CNY -533,158,456.93, an increase of 22.56% compared to the previous year[23]. - The cash flow from operating activities was CNY 227,377,262.86, down 11.72% from the previous year[23]. - The total assets at the end of 2022 were CNY 9,353,000,538.98, a decrease of 17.82% from the end of 2021[23]. - The net assets attributable to shareholders decreased by 18.35% to CNY 2,405,133,051.46 compared to the end of 2021[23]. - The basic earnings per share were CNY -0.81, an improvement of 22.12% from CNY -1.04 in the previous year[23]. - The total amount of non-recurring gains and losses for 2022 was approximately $19.95 million, a decrease from $42.11 million in 2021[29]. - The company reported a significant reduction in soft drink sales, with a 93.7% decrease in sales volume and a 100% drop in production volume[65]. - The company reported a total revenue of 3.689 billion CNY for the year 2022, reflecting a significant performance in the pharmaceutical sector[132]. - The company reported a total of 16,520,000 CNY for expected daily related transactions in 2022, with actual transactions amounting to 5,793,240 CNY for goods sold and 1,029,870 CNY for leasing[194]. Business Strategy and Operations - The company continues to focus on its core business despite challenges from the macro environment and rising raw material prices[3]. - The company emphasizes that its core competitiveness and main business have not undergone significant adverse changes[3]. - The company is focused on the modernization and industrialization of traditional Chinese medicine, supported by government policies aimed at enhancing the sector's development[32]. - The company is engaged in the research and development of T-cell immunotherapy drugs, with ongoing projects targeting soft tissue sarcoma and primary liver cancer[35]. - The company has established a comprehensive supply chain management system for the procurement of traditional Chinese medicine materials, ensuring quality and stability in supply[36]. - The company has maintained a stable product line, including antiviral oral liquids and various traditional Chinese medicine products, with no significant changes reported during the period[35]. - The company aims to modernize traditional Chinese medicine and expand its industry chain, including establishing standardized processing bases and logistics[96]. - The company is focusing on precision medicine, collaborating with medical institutions to develop clinical research projects and treatment centers[96]. - The company plans to explore new medical service models, including telemedicine and smart healthcare, to integrate resources from traditional and Western medicine[96]. - The company will focus on its core business, optimizing resource allocation to enhance scale efficiency and improve market share in the cold and cough product segments[98]. Research and Development - Ongoing clinical trials include KX02 for malignant glioma and a high-affinity TCR cell therapy for soft tissue sarcoma, indicating active R&D efforts[43][44]. - The company has established a complete TCR-T technology platform, achieving international advanced levels in tumor immunotherapy[45]. - The company’s subsidiary, Xiangxue Life Sciences, has a TCR-T cell immunotherapy product, TAEST16001, which is currently in Phase II clinical trials[57]. - The total R&D investment as a percentage of operating income increased to 6.12% from 4.60% in 2021[76]. - The company is committed to enhancing its research and development capabilities to drive innovation in the pharmaceutical industry[135]. Governance and Compliance - The company has established a governance structure that includes a board of directors, supervisory board, and management team, ensuring compliance with relevant laws and regulations[113]. - The company emphasizes the importance of information disclosure, adhering to regulations to provide accurate and timely information to investors[119]. - The company maintains good communication with investors through various channels, including performance briefings and investor visits, to keep them informed about its strategic direction and business developments[120]. - The company has received a warning from the China Securities Regulatory Commission regarding non-compliance with disclosure obligations, which highlights the need for improved governance[135]. - The company has established a compensation committee to determine the remuneration of directors and senior management based on performance and responsibilities[139]. Legal and Regulatory Issues - The company faces multiple legal disputes, including a significant lawsuit involving 300 million yuan related to investment rights and another arbitration case involving approximately 280 million yuan, which could affect its financial standing[108][109]. - The company has pledged assets such as the Yunpu plant and the Biological Island No. 1 plot to cover the amounts involved in the lawsuits, indicating a proactive approach to managing legal risks[109]. - The company has been fined 250,000 yuan for violating advertising laws, but this is not expected to have a major impact on operations[190]. - The company is actively seeking reasonable solutions for ongoing litigation and has engaged a professional legal team to protect its rights[191]. Employee and Management - The total number of employees at the end of the reporting period was 2,417[150]. - The company has a comprehensive annual training plan focusing on employee development, covering various skills and management capabilities[152]. - The company has optimized its training system to enhance employee learning efficiency and engagement through internal resources and new technologies[152]. - The company has established a performance evaluation system for senior management, with the compensation committee responsible for determining annual remuneration based on operational performance and management indicators[161]. Environmental Responsibility - The company invested approximately 1.35 million yuan in wastewater treatment, environmental testing, and solid/hazardous waste management in 2022[174]. - The company has implemented a wastewater treatment facility with a design capacity of 360 m³/d, ensuring compliance with national standards[172]. - The company reported no major environmental penalties during the reporting period[174]. - The company actively promotes green practices and resource efficiency, reflecting its commitment to environmental responsibility[175].

广州市香雪制药股份有限公司（以下简称"公司"）于 2023 年 4 月 22 日在 巨潮资讯网披露 2022 年年度报告及其摘要。为了让广大投资者更加深入全面地 了解公司 2022 年度的经营情况，公司将于 2023 年 5 月 5 日（星期五）下午 15 ：00-17：00 在深圳证券交易所提供的"互动易"平台以网络远程的方式举办 2022 年度业绩说明会，投资者可登录"互动易"网站（http://irm.cninfo.com.cn ）进入"云访谈"栏目参与本次年度业绩说明会。 出席本次年度业绩说明会的人员有：公司董事长兼总经理王永辉先生、独立 董事吴杰先生、董事会秘书徐力先生、财务总监牛晓燕女士。 为充分尊重投资者、提升交流的针对性，现就公司本次年度业绩说明会提前 向投资者公开征集问题，广泛听取投资者的意见和建议。投资者可提前登录"互 动易"网站进入公司本次年度业绩说明会页面进行提问，公司将在年度业绩说明 会上对投资者关注的问题进行回答。欢迎广大投资者积极参与！ 特此公告。 证券代码:300147 证券简称: 香雪制药 公告编号:2023-019 广州市香雪制药股份有限公司 关于举行 2022 年度业绩网 ...

证券代码：300147 证券简称：香雪制药 编号：20140828 广州市香雪制药股份有限公司投资者关系活动记录表 | --- | --- | --- | |----------------|------------------------------|--------------------------------------------------------| | | | | | 投资者关系活动 | | √特定对象调研 □分析师会议 | | 类别 | □媒体采访 □业绩说明会 | | | | □ | 新闻发布会 □路演活动 | | | □现场参观 | □ 一对一沟通 | | | □ | 其他 （请文字说明其他活动内容） | | 参与单位名称及 | | 华泰证券股份有限公司：杨烨辉、罗毅； | | 人员姓名 | 南方基金管理有限公司：韩海峰 | | | 时间 | 2014-8-28 16:00 | 至 18:00 | | 地点 | 公司会议室 | | | 上市公司接待人 | 董事会秘书：黄滨 | | | 员 | 副总经理：曾仑 | | | | 证券事务代表：徐力 | | | | 财务经理：卢锋 | | | ...

Group 1: Company Development Strategy - The company plans to focus on the development of traditional Chinese medicine while implementing a comprehensive strategy in the Chinese medicine resource sector, including full industry chain, full channel, and full category [2][3] - The company aims to actively expand into the cutting-edge biopharmaceutical field [3] Group 2: Clinical Research and Collaborations - The company is collaborating with Hospital 458 on a clinical research project for specific T cell adoptive immunotherapy targeting solid tumors, primarily focusing on liver cancer and non-small cell lung cancer caused by hepatitis B [3] - Phase one of the clinical trial has been completed, and data is currently being organized [3] Group 3: Mergers and Acquisitions - Mergers and acquisitions are considered a pathway for external growth and a strategic direction for the company [3][4] - The management will cautiously evaluate risks and benefits before proceeding with any mergers or acquisitions, focusing on targets that complement the company's products, technology, and channels [4] Group 4: Management Team Collaboration - The company signed an investment cooperation letter with Weng Gexin and his management team on July 10, 2015, to establish a joint venture in Beijing for prescription drug marketing [4] - The project is progressing as planned, with the company committed to timely information disclosure as per relevant regulations [4] Group 5: Financial Performance - The net profit of Bozhou Huqiao Pharmaceutical Co., Ltd. declined in the first half of 2015 due to preparations for a new GMP certification and restrictions on production capacity [4] - The decline in profit was also influenced by relevant national pharmaceutical industry policies [4]

Financial Performance - The company achieved a total revenue of 752.18 million yuan in the first half of 2015, representing a year-on-year growth of 0.77% [3] - The net profit attributable to shareholders was 93.07 million yuan, an increase of 3.76% compared to the same period last year [3] Marketing Strategy - The company is focusing on integrating marketing channels and strengthening channel management to enhance the marketing team for grassroots medical institutions [4] - Adjustments in sales strategies and market promotion are being made in response to new medical reform dynamics and drug procurement policies [4] Research and Development - Increased investment in R&D is ongoing, with a focus on accelerating the development and approval of new products [4] - The company is actively working on clinical research projects, including a phase one study on specific T cell therapy for solid tumors, with results expected around October [5] Management and Compliance - The company is enhancing production site management in accordance with the new GMP standards and has received the "Second Quality Award" from the Guangzhou Development Zone [4] - The first phase of the employee stock ownership plan was completed on June 18, 2015, and is being executed as per the asset management agreement [6] Future Plans - Mergers and acquisitions are considered a strategic direction for future growth, focusing on companies that complement the company's products, technology, and channels [6] - The company is preparing for potential growth in the second half of the year following capacity improvements and compliance with new GMP certifications [7]

证券代码：300147 证券简称：香雪制药 编号：20150721 广州市香雪制药股份有限公司投资者关系活动记录表 | --- | --- | --- | |----------------|------------------------------|------------------------------------------------------| | | | | | 投资者关系活动 | √特定对象调研 □分析师会议 | | | 类别 | □媒体采访 □业绩说明会 | | | | □ 新闻发布会 □路演活动 | | | | □现场参观 | □ 一对一沟通 | | | □ | 其他 （请文字说明其他活动内容） | | 参与单位名称及 | 大成基金管理有限公司：阳来军 | | | 人员姓名 | 招商基金管理有限公司：赵伟 | | | | | 广发证券资产管理（广东）有限公司：孙隽勃、刘宁 | | 时间 | 2015-7-21 | | | 地点 | 公司会议室 | | | 上市公司接待人 | 董事会秘书：黄滨 | | | 员 | 证券事务代表：徐力 | | | 投资者关系活动 | | （一）公司在中药 ...

Financial Performance - In the first half of 2015, the company achieved total operating revenue of 752.18 million yuan, a year-on-year increase of 0.77% [3] - The net profit attributable to shareholders was 93.07 million yuan, reflecting a year-on-year growth of 3.76% [3] Marketing Strategy - The company is closely monitoring changes in pharmaceutical industry policies and market strategies, adapting its marketing approach accordingly [3] - Efforts include strengthening channel management, enhancing the marketing team for grassroots medical institutions, and expanding networks to third parties [3] - A nationwide integrated pricing system is being established to manage prices of leading products [3] Research and Development - Increased investment in R&D to accelerate the development and approval of new products [3] - Progress on major R&D projects is reported to be smooth [3] Management and Quality Control - The company has strengthened production site management and safety education in accordance with the new GMP standards [4] - Continuous improvement of the product quality system has led to the company receiving the "Second Quality Award" from the Guangzhou Development Zone [4] Investor Relations - The slowdown in performance growth is attributed to an overall industry deceleration and the impact of refinancing on expansion speed [4] - The company is currently in the process of establishing Huacheng Bank, which is still under regulatory approval [4] - The first phase of the employee stock ownership plan was completed on June 18, 2015, with the company emphasizing its commitment to operational excellence to enhance shareholder value [5] - Plans to expand into the prescription drug market are underway, with a focus on collaboration with hospitals [5]

证券代码：300147 证券简称：香雪制药 编号：20150513 | --- | --- | --- | |----------------|------------------------------|----------------------------------------| | | | | | 投资者关系活动 | √特定对象调研 □分析师会议 | | | 类别 | □媒体采访 □业绩说明会 | | | | □ 新闻发布会 □路演活动 | | | | □现场参观 | □ 一对一沟通 | | | □ | 其他 （请文字说明其他活动内容） | | 参与单位名称及 | | 深圳市创海富信资产管理有限公司：许均华 | | 人员姓名 | | 南山资本东海长基投资基金：李思婷 | | | | 创金合信基金管理有限公司：皮劲松 | | | | 上海兴聚投资管理有限公司：朱节 | | | | 诺安基金管理有限公司：罗春蕾，杜佐远 | | | | 深圳前海汇杰达理资本有限公司：解睿 | | | 易方达基金管理有限公司：郭杰 | | | | 天弘基金管理有限公司：郭相博 | | | | 华创证券有限责任公司：王昊 | ...

Group 1: Company Development Plans - The company is focusing on the development of traditional Chinese medicine formula granules and is conducting research on processes and quality standards [3] - The company is optimistic about the market prospects for traditional Chinese medicine slices and aims to promote their industrialization [3] Group 2: Clinical Research and Collaborations - The first phase of clinical research on specific T cell adoptive immunotherapy for solid tumors in collaboration with Hospital 458 has been completed, and data is currently being organized [3] - The company is cautiously considering mergers and acquisitions as a path for external development, focusing on companies that complement its products, technology, and channels [4] Group 3: Strategic Partnerships - The company has signed letters of intent for cooperation with Hubei Tianji Traditional Chinese Medicine Slices Co., Ltd. and Anhui Dechang Pharmaceutical Slices Co., Ltd., and is progressing according to plan [4] Group 4: Sales and Growth - Jiujibiotech has made adjustments to its sales policies and is expected to achieve steady growth this year compared to last year [4] Group 5: Employee Stock Ownership Plan - The first phase of the employee stock ownership plan is being implemented according to the asset management contract [4]